Related Experiment Videos
Molecular targets of FTY720 (fingolimod)
M R Pitman1, J M Woodcock, A F Lopez
1Centre for Cancer Biology, SA Pathology, Frome Road, Adelaide SA 5000, Australia.
Current Molecular Medicine
|July 28, 2012
Summary
FTY720, a multiple sclerosis drug, also exhibits anti-cancer effects. These properties stem from its interaction with sphingosine 1-phosphate (S1P) receptors and other protein targets, independent of its immunosuppressive actions.
Area of Science:
- Pharmacology
- Immunology
- Oncology
Background:
- FTY720 is a first-line therapy for relapsing multiple sclerosis.
- Its immunosuppressive effects are mediated by sphingosine kinase 2 phosphorylation and sphingosine 1-phosphate (S1P) receptor 1 modulation, leading to lymphopenia.
- Emerging evidence suggests FTY720 possesses anti-cancer properties independent of S1P receptor activity.
Purpose of the Study:
- To review the direct protein targets of FTY720 responsible for its anti-cancer effects.
- To discuss other protein effectors contributing to FTY720's immunosuppressive and potential anti-cancer activities.
Main Methods:
- Literature review of studies investigating FTY720's biological effects.
- Analysis of research on FTY720's direct protein targets.
- Examination of studies exploring FTY720's mechanisms of action beyond S1P receptor modulation.
Main Results:
- Nonphosphorylated FTY720 modulates various protein targets, contributing to its anti-cancer effects.
- These anti-cancer effects are distinct from the S1P receptor-mediated immunosuppression.
- FTY720's multifaceted interactions with protein targets underpin its dual therapeutic potential.
Conclusions:
- FTY720 exhibits significant anti-cancer properties through mechanisms independent of its known immunosuppressive pathways.
- Understanding these diverse molecular targets is crucial for optimizing FTY720's therapeutic applications in both multiple sclerosis and cancer.
- Further research into FTY720's non-S1P receptor interactions may reveal novel therapeutic strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...